EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients

Michal Kyr iD, Peter Mudry, Kristyna Polaskova, Lenka Zdrazilova Dubska, Regina Demlova, Jana Kubatova, Eva Hlavackova, Katerina Cerna Pilatova, Pavel Mazanek, Klara Vejmelkova, Vitezslav Dusek, Pavel Tinka und 14 weitere

International Journal of Cancer · 15.10.2024 · 155 (8) · 1443-1454

DOI: 10.1002/ijc.35062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 03.07.2024. Verfasst von Michal Kyr und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Dendritic Cells, Cancer Vaccines, Neoplasms, Precision Medicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Školství, Mládeže a Tělovýchovy, HORIZON EUROPE, Ministerstvo Zdravotnictví České Republiky, FNBr.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A lot of hope for high‐risk cancers is being pinned on immunotherapy but the evidence in children is lacking due to the rarity and limited efficacy of single‐agent approaches. Here, we aim to assess the effectiveness of multimodal therapy comprising a personalized dendritic cell (DC) vaccine in children with relapsed and/or high‐risk solid tumors using the N‐of‐1 approach in real‐world scenario. A total of 160 evaluable events occurred in 48 patients during the 4‐year follow‐up. Overall survival of the cohort was 7.03 years. Disease control after vaccination was achieved in 53.8% patients. Comparative survival analysis showed the beneficial effect of DC vaccine beyond 2 years from initial diagnosis (HR = 0.53, P = .048) or in patients with disease control (HR = 0.16, P = .00053). A trend for synergistic effect with metronomic cyclophosphamide and/or vinblastine was indicated (HR = 0.60 P = .225). A strong synergistic effect was found for immune check‐point inhibitors (ICIs) after priming with the DC vaccine (HR = 0.40, P = .0047). In conclusion, the personalized DC vaccine was an effective component in the multimodal individualized treatment. Personalized DC vaccine was effective in less burdened or more indolent diseases with a favorable safety profile and synergized with metronomic and/or immunomodulating agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsCancer VaccinesNeoplasmsPrecision MedicineCyclophosphamideHumansMaleFemaleChildCombined Modality TherapyChild, PreschoolAdolescentAdministration, MetronomicImmunotherapyVinblastineInfantImmune Checkpoint InhibitorsFollow-Up Studies

Stichwörter der Autor:innen

N‐of‐1cancer vaccineimmunotherapymetronomic chemotherapyrare cancer

Substanzen

Cancer VaccinesCyclophosphamideVinblastineImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • International Clinical Research Centre, St. Anne's University Hospital in Brno, Brno, Czech Republic.
  • Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Department of Laboratory Medicine, University Hospital Brno, Brno, Czech Republic.
  • Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Central European Advanced Therapy and Immunotherapy Centre (CREATIC), Faculty of Medicine, Masaryk University, Brno, Czech Republic.

ORCID-Profile: Michal Kyr

Förderung

  • Ministerstvo Školství, Mládeže a Tělovýchovy
  • HORIZON EUROPE
  • Ministerstvo Zdravotnictví České Republiky, FNBr
  • HORIZON EUROPE Framework Programme
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Kyr, M., Mudry, P., Polaskova, K., Dubska, L. Z., Demlova, R., Kubatova, J., Hlavackova, E., Pilatova, K. C., Mazanek, P., Vejmelkova, K., Dusek, V., Tinka, P., Balaz, M., Merta, T., Kuttnerova, Z., Turekova, T., Pavelka, Z., Pokorna, P., Palova, H., …, & Sterba, J. (2024). Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients. International Journal of Cancer, 155(8), 1443-1454. https://doi.org/10.1002/ijc.35062

Vancouver

Kyr M, Mudry P, Polaskova K, Dubska LZ, Demlova R, Kubatova J, et al. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients. International Journal of Cancer. 2024;155(8):1443-1454. doi:10.1002/ijc.35062

BibTeX
@article{Kyr2024,
  author = {Kyr, Michal and Mudry, Peter and Polaskova, Kristyna and Dubska, Lenka Zdrazilova and Demlova, Regina and Kubatova, Jana and Hlavackova, Eva and Pilatova, Katerina Cerna and Mazanek, Pavel and Vejmelkova, Klara and Dusek, Vitezslav and Tinka, Pavel and Balaz, Martin and Merta, Tomas and Kuttnerova, Zuzana and Turekova, Terezia and Pavelka, Zdenek and Pokorna, Petra and Palova, Hana and Mlnarikova, Marie and Jezova, Marta and Kellnerova, Renata and Kozakova, Sarka and Slaby, Ondrej and Valik, Dalibor and Sterba, Jaroslav},
  title = {Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {155},
  number = {8},
  pages = {1443--1454},
  doi = {10.1002/ijc.35062}
}
Kostenlos starten →